Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis

Inclusion Criteria: * Clinical and imaging diagnosis of liver cirrhosis and esophagogastric varices, with at least one previous episode of esophagogastric variceal bleeding * Combined with portal vein thrombosis and D-dimer \> 0.8mg/L * Endoscopic evaluation reveals a high risk of variceal bleeding, and endoscopic treatment is performed to prevent rebleeding of esophagogastric varices * Signed informed consent form Exclusion Criteria: * Received other antithrombotic therapies before (including warfarin, aspirin, low-molecular-weight heparin, etc.) * Combined with hepatocellular carcinoma or other malignancy * Combined with portal cavernoma * Combined with severe life-threatening diseases of circulatory, hematological and respiratory system * Combined with diseases requiring anticoagulant therapy, such as acute portal vein thrombosis, atrial fibrillation, lower extremity venous thrombosis, and pulmonary embolism * Received TIPS or liver transplantation or splenectomy * With contraindications to anticoagulant therapy (uncontrollable active bleeding, severe hepatic insufficiency, renal insufficiency, etc.) * Currently taking immunosuppressive agents, or medications that affect cytochrome P450 (including azole antifungals and protease inhibitors), or strong inducers of CYP3A4 (including rifampicin, phenytoin, carbamazepine, etc.)